
Constantinos Zamboglou
@czamboglou
Father of 3 | Medical Director @goc_cy | Research group leader @Uniklinik_Fr | GU RadOnc | my views
ID: 1530641807444516866
28-05-2022 20:07:09
405 Tweet
516 Followers
475 Following

Danny Vesprini Rubén Del Castillo Piet Ost Paul Sargos Alison Tree 💙 Pierre Blanchard, MD Vérane Achard Vedang Murthy and many many more on X! Special thx to Constantinos Zamboglou organizing this epic event!


🆒 making friends, having fun…and giving rise to an international dream team 🚀 #ESTRO2025 🙏 to Constantinos Zamboglou🇨🇾, Jennifer Le Guévelou🇫🇷, Cédric Draulans🇧🇪, Simon Spohn🇩🇪, Binnaz Yasar🇬🇧, Astrid Carsson🇸🇪, Casper Reijnen🇳🇱, Denis Panizza🇮🇹, 💖😍duygu💖🇮🇹




Alfonso Gomez-Iturriaga Priyamvada Maitre Mark Storey nature gaganprakash We don't have access to it. But Constantinos Zamboglou is using ArteraAI Prostate Cancer and Prostatic Diseases

Paul Sargos Neeraj Agarwal, MD, FASCO Piet Ost ASCO Nick James also on @Prof-Nick-James.bsky.social AttardLab OncoAlert UroToday.com PCF Science Sumanta K. Pal, MD, FASCO Toni Choueiri, MD GU Cancer Research Program @HuntsmanCancer silke gillessen Yüksel Ürün Arun Azad Tian Zhang, MD, MHS Daniel Castellano Daniel E Spratt Ian Davis Constantinos Zamboglou A perfect answer to the question at the perfect moment. This can be very helpful Prostate Cancer and Prostatic Diseases x.com/VedangMurthy/s…

Thanks Sophia Kamran, MD & Constantinos Zamboglou for this invitation to highlight keypoints and thoughts about ADT and Post-op RT. sciencedirect.com/science/articl… ✨✨✨✨✨✨✨✨✨✨


Happy to share our review on hypo- and ultra-hypofractionation for prostate cancer radiotherapy, just published in Seminars in Radiation Oncology Full-text authors.elsevier.com/a/1lFrI3lXQoc1… Harshani Green 💙 @harshanigreen.bsky.social Alison Tree 💙 The Royal Marsden NHS Foundation Trust The ICR Elsevier Oncology Advance


Constantinos Zamboglou Anna Dornisch Agree nice HDR +s (but no RCT to prove patient impact). Invisible tumors also an issue for microboost Not sure about large GTV near rectum—are we confident toxicity is really less w HDR to that prostate-rectum interface than with VMAT? Is spacer helpful w one or both approaches?

Honored to be a co-editor along with Constantinos Zamboglou for this Issue on Prostate Cancer, now available in Seminars in Radiation Oncology. Thank you to @ANViswanathan for the invitation and support. 1/n


Constantinos Zamboglou Anna Dornisch Thanks! Agree with above. We just opened the RAD-TARGET trial UC San Diego Health Moores Cancer Center: phase II RCT evaluating ⬆️ dose to visible tumor (RSI+PSMA) + ⬇️ dose to benign-appearing prostate Anna Dornisch Rana McKay, MD, FASCO Michael Liss

During residency, when modems crackled and PubMed barely loaded, I relied on Sem in Rad Oncol for the latest info. Contributing 2 articles to its latest issue on #prostatecancer is a full-circle moment. 🙏🏼 What Sophia Kamran, MD and Constantinos Zamboglou have put together is a masterpiece.


Poll for the group. When treating whole pelvis with SBRT/UHRT do you contour: David Yang Paul Nguyen Deep Chakrabarti Harshani Green 💙 @harshanigreen.bsky.social ; Alison Tree 💙 Amar Kishan Vedang Murthy Himanshu Nagar Constantinos Zamboglou Karen Hoffman, MD, MHSc, MPH

Dr. Andrew Loblaw David Yang Paul Nguyen Deep Chakrabarti Harshani Green 💙 @harshanigreen.bsky.social Alison Tree 💙 Amar Kishan Himanshu Nagar Constantinos Zamboglou Karen Hoffman, MD, MHSc, MPH x.com/VedangMurthy/s… Bag, always the bag. 😊


What a great summary on treatment of #Oligometastatic #ProstateCancer ! Congrats Vedang Murthy Maneesh Singh Piet Ost Good learning for every Resident and Senior Faculty! 💪🏻💪🏻
